Pharmacotherapy as the mainstay in the management of breast cancer suffers from various\ndrawbacks, including non-targeted biodistribution, narrow therapeutic and safety windows, and\nalso resistance to treatment. Thus, alleviation of the constraints from the pharmacodynamic and\npharmacokinetic profile of classical anti-cancer drugs could lead to improvements in efficacy and\npatient survival in malignancies. Moreover, modifications in the genetic pathophysiology of cancer\nvia administration of small nucleic acids might pave the way towards higher response rates to\nchemotherapeutics. Inorganic pH-dependent carbonate apatite (CA) nanoparticles were utilized\nin this study to efficiently deliver various classes of therapeutics into cancer cells. Co-delivery of\ndrugs and genetic materials was successfully attained through a carbonate apatite delivery device.\nOn 4T1 cells, siRNAs against AKT and ERBB2 plus paclitaxel or docetaxel resulted in the largest\nincrease in anti-cancer effects compared to CA/paclitaxel or CA/docetaxel. Therefore, these ingredients\nwere selected for further in vivo investigations. Animals receiving injections of CA/paclitaxel or\nCA/docetaxel loaded with siRNAs against AKT and ERBB2 possessed significantly smaller tumors\ncompared toCA/drug-treated mice. Interestingly, synergistic interactions in target protein knock down\nwith combinations of CA/AKT/paclitaxel, CA/ERBB2/docetaxel were documented via western blotting.
Loading....